|
|
||||||||||
|
The Math Shows IWV Can Go To $327 The Online Investor Staff - Fri., May. 10, 7:07 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $327.02 per unit. Read More » Analysts Anticipate VTWG Will Reach $230 The Online Investor Staff - Tue., Apr. 9, 9:04 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $229.78 per unit. Read More » Commit To Purchase UroGen Pharma At $10, Earn 20.3% Annualized Using Options The Online Investor Staff - Wed., Apr. 3, 12:23 PM URGN Makes Notable Cross Below Critical Moving Average The Online Investor Staff - Thu., Mar. 14, 6:19 PM IBBQ's Holdings Could Mean 29% Gain Potential The Online Investor Staff - Thu., Mar. 7, 7:26 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $28.66 per unit. Read More » Add Up The Parts: VTWG Could Be Worth $214 The Online Investor Staff - Thu., Feb. 1, 8:16 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $214.05 per unit. Read More » Commit To Buy UroGen Pharma At $12.50, Earn 27.8% Annualized Using Options The Online Investor Staff - Wed., Jan. 3, 1:51 PM VTWV's Holdings Imply 21% Gain Potential The Online Investor Staff - Thu., Nov. 30, 6:59 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $147.94 per unit. Read More » RSI Alert: UroGen Pharma (URGN) Now Oversold The Online Investor Staff - Thu., Nov. 2, 11:52 AM UroGen Pharma Breaks Below 200-Day Moving Average - Notable for URGN The Online Investor Staff - Tue., Oct. 17, 5:31 PM Oversold Conditions For UroGen Pharma (URGN) The Online Investor Staff - Wed., Oct. 11, 11:54 AM Commit To Buy UroGen Pharma At $12.50, Earn 36.3% Annualized Using Options The Online Investor Staff - Thu., Oct. 5, 1:44 PM Analysts Expect IBBQ Will Reach $28 The Online Investor Staff - Thu., Sep. 28, 6:58 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $27.67 per unit. Read More » Surprising Analyst 12-Month Target For SPDW The Online Investor Staff - Tue., Aug. 22, 8:40 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR Portfolio Developed World ex-US ETF (SPDW), we found that the implied analyst target price for the ETF based upon its underlying holdings is $36.69 per unit. Read More » Noteworthy Wednesday Option Activity: URGN, VICR, ARCB The Online Investor Staff - Wed., Jul. 26, 3:20 PM Analysts Expect 38% Gains Ahead For The Holdings of IBBQ The Online Investor Staff - Wed., Jul. 12, 7:39 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $27.92 per unit. Read More » Notable Two Hundred Day Moving Average Cross - URGN The Online Investor Staff - Tue., Jul. 11, 4:48 PM Analysts Anticipate IBBQ Will Reach $28 The Online Investor Staff - Tue., Jun. 6, 7:52 AM Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $27.89 per unit. Read More »
|
|
||||||||||
Free Email Alerts:
Articles | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.